KRAS and non-small cell squamous lung carcinoma: LKB1 has been proven to be the most prevalent driver gene of resistance to PD-1 inhibitor in KRAS-mutant lung adenocarcinoma [16], while in LKB1-mutant non-squamous non-small cell lung cancer (mnsNSCLC), pembrolizumab did not improve the PFS and OS of patients administered platinum-pemetrexed chemotherapy [91].